The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma.
 
Guru P. Sonpavde
Employment - Myriad Genetics (I)
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; Pfizer; Scholar Rock; Seagen
Speakers' Bureau - Medscape; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Janssen (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; Debiopharm Group; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Phoebe Wright
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Zsolt Hepp
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Nancy N. Chang
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Candice Willmon
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Steven Sesterhenn
Employment - Astellas Pharma
Stock and Other Ownership Interests - Merck; Seagen
 
Yutong Liu
Employment - Genesis Research
Consulting or Advisory Role - Seagen (Inst)
 
Alicia K. Morgans
Honoraria - Advanced Accelerator Applications; Astellas Pharma; Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Exelixis; Genentech; Janssen; Janssen; Janssen Oncology; Merck; Myovant Sciences; Pfizer; Sanofi
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Exelixis; Janssen; Lantheus Medical Imaging; Merck; Myovant Sciences; Myovant Sciences; Myriad Genetics; Novartis; Sanofi
Research Funding - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Dendreon; Genentech; Myovant Sciences; Sanofi; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Sanofi